Although there are not many phase II clinical trials on immunotherapies for thymic epithelial tumors, several phase II clinical trials on the efficacy of immunotherapies in patients with advanced thymic carcinoma still reveal the relationship between PD-L1 and the benefit of immunotherapy. The gene discussed is CD274; the disease is thymic carcinoma.